Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Signs and symptoms  





2 Causes  





3 Diagnosis  



3.1  Units  







4 Treatment  





5 References  





6 External links  














Hyperphosphatemia






العربية
Català
Deutsch
Español
Français

Italiano
עברית
Bahasa Melayu

ି
Polski
Português
Slovenščina
Српски / srpski
Suomi
Svenska
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Hyperphosphatemia
Phosphate group chemical structure
SpecialtyEndocrinology, nephrology
SymptomsNone, calcium deposits, muscle spasms[1]
ComplicationsLow blood calcium[1]
CausesKidney failure, pseudohypoparathyroidism, hypoparathyroidism, diabetic ketoacidosis, tumor lysis syndrome, rhabdomyolysis[1]
Diagnostic methodBlood phosphate > 1.46 mmol/L (4.5 mg/dL)[1]
Differential diagnosisHigh blood lipids, high blood protein, high blood bilirubin[1]
TreatmentDecreasing intake, calcium carbonate[1]
FrequencyUnclear[2]

Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood.[1] Most people have no symptoms while others develop calcium deposits in the soft tissue.[1] Often there is also low calcium levels which can result in muscle spasms.[1]

Causes include kidney failure, pseudohypoparathyroidism, hypoparathyroidism, diabetic ketoacidosis, tumor lysis syndrome, and rhabdomyolysis.[1] Diagnosis is generally based on a blood phosphate levels of greater than 1.46 mmol/L (4.5 mg/dL).[1] Levels may appear falsely elevated with high blood lipid levels, high blood protein levels, or high blood bilirubin levels.[1]

Treatment may include eating a phosphate low diet and antacids, like calcium carbonate, that bind phosphate.[1] Occasionally intravenous normal salineordialysis may be used.[1] How commonly it occurs is unclear.[2]

Signs and symptoms[edit]

Signs and symptoms include ectopic calcification, secondary hyperparathyroidism, and renal osteodystrophy. Abnormalities in phosphate metabolism such as hyperphosphatemia are included in the definition of the new chronic kidney disease–mineral and bone disorder (CKD–MBD).[3]

Causes[edit]

Impaired renal phosphate excretion[4]
Massive extracellular fluid phosphate loads[4]

Hypoparathyroidism: In this situation, there are low levels of parathyroid hormone (PTH). PTH normally inhibits reabsorption of phosphate by the kidney. Therefore, without enough PTH there is more reabsorption of the phosphate leading to a high phosphate level in the blood.[citation needed]

Chronic kidney failure: When the kidneys are not working well, there will be increased phosphate retention.[citation needed]

Drugs: hyperphosphatemia can also be caused by taking oral sodium phosphate solutions prescribed for bowel preparation for colonoscopy in children.

Diagnosis[edit]

The diagnosis of hyperphosphatemia is made through measuring the concentration of phosphate in the blood. A phosphate concentration greater than 1.46 mmol/L (4.5 mg/dL) is indicative of hyperphosphatemia, though further tests may be needed to identify the underlying cause of the elevated phosphate levels.[5] It is considered significant when levels are greater than 1.6 mmol/L (5 mg/dL).[2]

Units[edit]

Phosphates in blood exist in a chemical equilibrium of hydrogen phosphate (HPO42–) and dihydrogen phosphate (H2PO4), which have different masses. Phosphate (PO43–) and phosphoric acid (H3PO4) are not present in significant amounts. Thus millimoles per liter (mmol/L) are often used to denote the phosphate concententration. If milligrams per decililiter (mg/dL) is used, it often denotes the mass of phosphorus bound to phosphates, but not the mass of some individual phosphate.[6]

Treatment[edit]

High phosphate levels can be avoided with phosphate binders and dietary restriction of phosphate.[5] If the kidneys are operating normally, a saline diuresis can be induced to renally eliminate the excess phosphate. In extreme cases, the blood can be filtered in a process called hemodialysis, removing the excess phosphate.[5] Phosphate-binding medications include sevelamer, lanthanum carbonate, calcium carbonate, and calcium acetate.[7] Previously aluminum hydroxide was the medication of choice, but its use has been largely abandoned due to the increased risk of aluminum toxicity.[8]

References[edit]

  1. ^ a b c d e f g h i j k l m n "Hyperphosphatemia". Merck Manuals Professional Edition. Retrieved 27 October 2018.
  • ^ a b c Ronco C, Bellomo R, Kellum JA (2008). SPEC - Critical Care Nephrology Expert Consult (Book Program) Pincard. Elsevier Health Sciences. p. 533. ISBN 978-1437711110.
  • ^ "KDIGO Guideline for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)". Archived from the original on 4 March 2017. Retrieved 7 February 2016. {{cite journal}}: Cite journal requires |journal= (help)
  • ^ a b Longo et al., Harrison's Principles of Internal Medicine, 18th ed., p.3089
  • ^ a b c "Hyperphosphatemia - Endocrine and Metabolic Disorders - Merck Manuals Professional Edition". Merck Manuals Professional Edition. Merck Sharp & Dohme Corp. Retrieved 23 October 2017.
  • ^ Lerma EV, et al. (2019). Nephrology secrets (4th ed.). Elsevier. pp. 532–533. ISBN 9780323478717.
  • ^ Critical care nursing : diagnosis and management. Urden, Linda Diann. (7th ed.). St. Louis, Mo.: Elsevier/Mosby. 2014. p. 716. ISBN 978-0-323-09178-7. OCLC 830669119.{{cite book}}: CS1 maint: others (link)
  • ^ Hutchison AJ, Smith CP, Brenchley PE (October 2011). "Pharmacology, efficacy and safety of oral phosphate binders". Nature Reviews Nephrology. 7 (10): 578–589. doi:10.1038/nrneph.2011.112. ISSN 1759-5061. PMID 21894188. S2CID 19833271.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Hyperphosphatemia&oldid=1229243093"

    Category: 
    Electrolyte disturbances
    Hidden categories: 
    CS1 errors: missing periodical
    CS1 maint: others
    Articles with short description
    Short description is different from Wikidata
    All articles with unsourced statements
    Articles with unsourced statements from June 2022
    Wikipedia medicine articles ready to translate
     



    This page was last edited on 15 June 2024, at 18:05 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki